Our study is the first real-world investigation to compare the impact of perioperative chemotherapy and EGFR-TKIs on the OS of patients with EGFR-mutant stage III NSCLC after incorporating pathological factors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.